SCI-PUB

Plasma Cell Disorders

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1.

Teclistamab, an off-the-shelf B-cell maturation antigen (BCMA) × CD3 bispecific antibody that mediates T-cell activation and subsequent lysis of BCMA-expressing myeloma cells, is approved for the treatment of patients with relapsed/refractory multiple myeloma (RRMM)...

DOI: 10.1182/blood.2023022823

Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, Lau OS, Nielsen K, Davis C, Patel JH, Banerjee A, Stephenson T, Uhlar C, Kobos R, Goldberg JD, Pei L, Trancucci D, Girgis S, Wang Lin SX, Wu LS, Moreau P, Usmani SZ, Bahlis N

Blood, 2024-04-26

NEW

[Prioritizing the diagnosis and treatment of cardiac amyloidosis].

No abstract text is available for this article

DOI: 10.3760/cma.j.cn112148-20231224-00523

Tian Z, Zhang SY

Zhonghua xin xue guan bing za zhi, 2024-04-26

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.

IRd appeared to be effective in RRMM patients in routine clinical practice regardless of prior lenalidomide or PI exposure, with better outcomes seen in lenalidomide- and/or PI-nonrefractory versus refractory patients.

DOI: 10.1111/ejh.14214

Lee HC, Ramasamy K, Macro M, Davies FE, Abonour R, van Rhee F, Hungria VTM, Puig N, Ren K, Silar J, Enwemadu V, Cherepanov D, Leleu X

European journal of haematology, 2024-04-25

Clonal Hematopoiesis of Indeterminate Potential in Patients with Immunoglobulin Light Chain AL Amyloidosis.

Immunoglobulin light chain (AL) amyloidosis is characterized by the deposition of misfolded monoclonal free light chains, with cardiac complications accounting for patients' mortality...

DOI: 10.1182/bloodadvances.2024012840

Lopedote P, Evans B, Marchetti A, Chen T, Moscvin M, Boullt S, Bolli N, Bianchi G

Blood advances, 2024-04-25

Treatment of transthyretin cardiac amyloidosis.

PURPOSE OF REVIEW: Tafamidis is currently the only approved disease-modifying treatment for ATTR-CM...

DOI: 10.1097/HCO.0000000000001156

Bampatsias D, Wardhere A, Maurer MS

Current opinion in cardiology, 2024-04-25

Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.

WHAT IS THIS SUMMARY ABOUT?: This plain language summary describes the results of a Phase 3 study called KarMMa-3.

DOI: 10.2217/fon-2023-0954

Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S

Future oncology (London, England), 2024-04-25

Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis.

To evaluate whether patients with multiple myeloma (MM) could benefit from tandem autologous hematopoietic stem cell transplantation (auto-HSCT), PubMed, Embase, Web of Science and Cochrane Library databases were systematically searched, and 10 eligible studies were included after data extraction and quality evaluation...

DOI: 10.1080/16078454.2024.2343164

Li H, Zheng Y, Gao K, Tian C

Hematology (Amsterdam, Netherlands), 2024-04-25

Construction of immune-related gene pairs signature to predict the overall survival of multiple myeloma patients based on whole bone marrow gene expression profiling.

Multiple myeloma (MM) is a plasma cell dyscrasia that is characterized by the uncontrolled proliferation of malignant PCs in the bone marrow...

DOI: 10.1007/s00438-024-02140-7

Jafari-Raddani F, Davoodi-Moghaddam Z, Bashash D

Molecular genetics and genomics : MGG, 2024-04-25

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.

In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM)...

DOI: 10.1038/s41408-024-01030-w

Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakub

Blood cancer journal, 2024-04-25

Analysis of the efficacy of separation surgery for severe neurological compression in multiple myeloma: a retrospective analysis of 35 cases.

Separation surgery effectively alleviates pain, improves neurological function, and enhances the quality of life in patients with ESCC graded ≥ 2 due to MM.

DOI: 10.1007/s00586-024-08269-8

Liu JP, Yao XC, Wu Y, Xu ZY, Li M, Shi M, Ren J, Du XR

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2024-04-25

How to manage prolonged immune effector cell-associated hematotoxicity (ICAHT) related to BCMA-directed myeloma therapy.

No abstract text is available for this article

DOI: 10.1080/14737140.2024.2344650

Davis JA, McGann M, Marini J, Hashmi H

Expert review of anticancer therapy, 2024-04-23

Наверх